Basket | Login


Alector starts Phase I trial of AL002 for AD

Thursday 15 November 2018

On 15 November, Alector, a biotechnology company developing immuno- neurology therapies to treat neurodegenerative diseases, announced the launch of its Phase I trial of AL002 for the treatment of Alzheimer’s disease (AD). AL002 is an antibody that targets TREM2 (triggering receptor expressed on myeloid cells 2) which is a receptor expressed on microglia - the immune cells that reside in the brain. The Phase I study, called the INVOKE study, is a multi-centre, randomised, double-blind and placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL002 in healthy adults and people with mild to moderate AD. The company expects to recruit approximately 52 participants. The primary outcome is the evaluation of the safety and tolerability of AL002 measured by the incidence of adverse events and dose limiting adverse event (DLAEs).